Pfizer considers purchase of India's Agila Specialties - report

Tue Jan 15, 2013 2:10am IST

A view of the Belgian headquarters of U.S. pharmaceutical giant Pfizer, in Brussels January 23, 2007. REUTERS/Francois Lenoir/Files

A view of the Belgian headquarters of U.S. pharmaceutical giant Pfizer, in Brussels January 23, 2007.

Credit: Reuters/Francois Lenoir/Files

Related Topics

Stocks

   

REUTERS - Pfizer Inc is considering buying India's Agila Specialties, the injectable-medicines unit of Indian drug supplier Strides Arcolab Ltd (STAR.NS), for a possible price of $2 billion, Bloomberg reported on Monday.

Pfizer is doing due diligence and a deal could be reached this quarter, Bloomberg reported, citing unnamed sources.

A Pfizer spokeswoman said the company does not comment on market rumours or speculation.

Agila makes cancer treatments and antibiotics, Bloomberg said.

Pfizer shares were up 23 cents at $26.75 on the New York Stock Exchange. (Reporting By Caroline Humer; editing by John Wallace)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

India-WTO Row

REUTERS SHOWCASE

Market Eye

Market Eye

Nifty falls most in nearly 3-1/2 weeks; Sensex down over 400 points  Full Article 

Factory Activity

Factory Activity

Factories post fastest growth for 17 months in July  Full Article 

Reviving Infosys

Reviving Infosys

CEO Sikka says to improve business with new growth avenues  Full Article 

Outlook Slashed

Outlook Slashed

ArcelorMittal cuts outlook as ore prices hit mining  Full Article 

Re-gaining Momentum

Re-gaining Momentum

China, Asian factory growth gathers pace; Europe falters  Full Article 

Car Launch Ahead

Car Launch Ahead

Tata Motors bets on new sedan to revive weak India sales.  Full Article 

Gold Smuggling

Gold Smuggling

In cat-and-mouse game, India uncovers new gold smuggling route.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage